By Sarah Max
March 12, 2015
The Ebola crisis underscored a problem that vexes experts in global health: Vaccines are one of the most cost-effective ways to save lives, especially in developing countries, yet traditional vaccines can take years to develop.
So when the Bill & Melinda Gates Foundation came across CureVac, a biopharmaceutical company working on technology that could produce vaccines faster, cheaper and more effectively, it not only took note — it took a stake in the company.